Page 3 - Syncona Ltd News Today

/PRNewswire/ -- The gene therapy market size is expected to grow by USD 4.61 billion from 2022 to 2027. In addition, the momentum of the market will progress...

Syncona Ltd - London-based investor in healthcare companies - Says Syncona Investment Management Ltd has submitted a non-binding proposal to acquire the entire remaining share capital of Freeline...

SwanBio Therapeutics, a gene therapy company developing AAV-based therapies for the treatment of devastating, inherited neurological conditions, today announced the addition of two industry...

PHILADELPHIA--(BUSINESS WIRE)--Oct 16, 2023--

Synconaltd.com October 2023 Cautionary statement ...

PHILADELPHIA--(BUSINESS WIRE)--Oct 4, 2023--

Independent Data Safety Monitoring Board recommended dose escalation First patient in cohort 2 has received SBT101 Majority investor Syncona providing new...

Syncona Ltd - London-based investor in healthcare companies - Launches share buyback programme worth up to GBP40.0 million, to be conducted by Numis Securities Ltd. Says core focus remains on...

Purespring appoints Fredrik Erlandsson as Chief Medical Officer and Peter Mulcahy as Chief People Officer Appointments of Fredrik and Peter complete build-out of senior team London— 6 September 2023— Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, has appointed Fredrik Erlandson as Chief Medical Officer and Peter Mulcahy as Chief People Officer. These two key additional appointments complete Purespring’s le...

Appointments of Fredrik and Peter complete build-out of senior team London- 6 September 2023- Purespring Therapeutics, a pioneering gene therapy company focused on transforming...